Compare Abbott Laboratories (ABT) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Starbucks Corp — how do they compare? Abbott Laboratories trades at $110.23 (market cap $187.95B), while Starbucks Corp trades at $107.2 (market cap $121.59B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Starbucks Corp pays the higher dividend (2.33%). Which is the better fit depends on your goals.
| ABT | SBUX | |
|---|---|---|
Market Cap | $187.95B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $108.37 |
52-Week Low | $82.57 | $78.46 |
Enterprise Value | $214.96B | $140.42B |
Dividend Yield | 2.32% | 2.33% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Starbucks (SBUX) trades at $104.65, down 0.88% on the day, with technical indicators neutral and support near $104. The company reported mixed quarterly EPS results, beating in Q1 and Q2 2026 but missing in Q4 2025, while raising its fiscal 2026 outlook. Revenue grew to $37.18B in 2025, but net income fell to $1.86B, compressing margins. Analyst consensus is a Buy with a $113.60 price target, citing a traffic recovery and cost initiatives.
The outlook hinges on sustaining sales momentum and margin expansion amid high valuation multiples. Risks include execution on turnaround plans, competitive pressure, and debt levels. Upside potential exists if earnings recovery continues, but investors face volatility from macroeconomic headwinds and premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
